Type 2 diabetes and heart failure: Challenges and solutions

Current Cardiology Reviews

Volumn 12, Issue 3, 2016, Pages 249-255

  Thomas, Merlin C ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Congestive cardiac failure; Diabetes; Diabetic cardiomyopathy; Diastolic dysfunction; Heart failure

Indexed keywords

SODIUM GLUCOSE COTRANSPORTER 2;

ADRENERGIC SYSTEM; ANEMIA; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETES MELLITUS, TYPE 2; HOSPITALIZATION; HYPERGLYCEMIA; RISK FACTOR;

ANEMIA; DIABETES MELLITUS, TYPE 2; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPERGLYCEMIA; HYPERTENSION; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84981541088     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/1573403X12666160606120254     Document Type: Article

References (69)

1. McAlister FA, Teo KK, Taher M, et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J 1999; 138(1 Pt 1): 87-94.
2. Leyden E. Asthma und Diabetes mellitus. Z Klin Med 1881; 3: 358-64.
3. Thrainsdottir IS, Aspelund T, Thorgeirsson G, et al. The association between glucose abnormalities and heart failure in the population- based Reykjavik study. Diabetes Care 2005; 28(3): 612-6.
4. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34(1): 29-34.
5. Dei Cas A, Khan SS, Butler J, et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail 2015; 3(2): 136-45.
6. Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol 2015; 3(2): 105-13.
7. Dries DL, Sweitzer NK, Drazner MH, et al. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001; 38(2): 421-8.
8. Varela-Roman A, Grigorian Shamagian L, Barge Caballero E, et al. Influence of diabetes on the survival of patients hospitalized with heart failure: a 12-year study. Eur J Heart Fail 2005; 7(5): 859-64.
9. Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000; 101(19): 2271-6.
10. Emerging Risk Factors C, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular dis ease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375(9733): 2215-22.
11. Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30(6): 595-602.
12. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014; 57(4): 660-71.
13. Mandavia CH, Aroor AR, Demarco VG, et al. Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci 2013; 92(11): 601-8.
14. Lind M, Bounias I, Olsson M, et al. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 2011; 378(9786): 140-6.
15. Erqou S, Lee CT, Suffoletto M, et al. Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta-analysis. Eur J Heart Fail 2013; 15(2): 185-93.
16. Aguilar D, Bozkurt B, Ramasubbu K, et al. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol 2009; 54(5): 422-8.
17. Udell JA, Cavender MA, Bhatt DL, et al. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015; 3(5): 356-66.
18. Kaul S, Bolger AF, Herrington D, et al. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 2010; 121(16): 1868-77.
19. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117-28.
20. Writing Committee M, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128(16): e240-327.
21. Baker DW. Prevention of heart failure. J Card Fail 2002; 8(5): 333-46.
22. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313(6): 603-15.
23. Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009; 54(19): 1747-62.
24. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138(7): 542-9.
25. Carr AA, Kowey PR, Devereux RB, et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 2005; 96(11): 1530-6.
26. Group AS, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1575-85.
27. Tamargo J, Caballero R, Delpon E. New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors -- hype or hope? Discov Med 2014; 18(100): 249-54.
28. Yang X, Ma RC, So WY, et al. Development and validation of a risk score for hospitalization for heart failure in patients with Type 2 diabetes mellitus. Cardiovasc Diabetol 2008; 7: 9.
29. Massie BM. Obesity and heart failure--risk factor or mechanism? N Engl J Med 2002; 347(5): 358-9.
30. Glogner S, Rosengren A, Olsson M, et al. The association between BMI and hospitalization for heart failure in 83,021 persons with Type 2 diabetes: a population-based study from the Swedish National Diabetes Registry. Diabet Med 2014; 31(5): 586-94.
31. Gupta PP, Fonarow GC, Horwich TB. Obesity and the obesity paradox in heart failure. Can J Cardiol 2015; 31(2): 195-202.
32. Wang TJ. The obesity paradox in heart failure: weighing the evidence. J Am Coll Cardiol 2014; 64(25): 2750-2.
33. Look ARG, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369(2): 145-54.
34. Grapsa J, Tan TC, Paschou SA, et al. The effect of bariatric surgery on echocardiographic indices: a review of the literature. Eur J Clin Invest 2013; 43(11): 1224-30.
35. Hockensmith ML, Estacio RO, Mehler P, et al. Albuminuria as a predictor of heart failure hospitalizations in patients with type 2 diabetes. J Card Fail 2004; 10(2): 126-31.
36. Thomas MC. Anemia in diabetes: marker or mediator of microvascular disease? Nat Clin Pract Nephrol 2007; 3(1): 20-30.
37. Report KD. KEEP 2004 Data Report (2005). Amrican J Kidney Dis 2005; 45(Suppl 2)((3)): S8-S13 and S76-S7.
38. Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162(12): 1401-8.
39. Bosman DR, Winkler AS, Marsden JT, et al. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24(3): 495-9.
40. Ishimura E, Nishizawa Y, Okuno S, et al. Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. J Nephrol 1998; 11(2): 83-6.
41. Collins AJ. Annual data report: National Kidney Foundation Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2012; 42(5 Suppl. 4): S52-S5.
42. Thomas MC, MacIsaac RJ, Tsalamandris C, et al. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care 2003; 26(4): 1164-9.
43. Anand I, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004; 110(2): 149-54.
44. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008; 52(10): 818-27.
45. Lundin AP. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy. Semin Nephrol 1989; 9(1 Suppl 1): 22-9.
46. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 1990; 300(6724): 573-8.
47. Srivastava PM, Thomas MC, Calafiore P, et al. Diastolic dysfunction is associated with anaemia in patients with Type II diabetes. Clin Sci (Lond) 2005; 110(1): 109-16.
48. Sandgren PE, Murray AM, Herzog CA, et al. Anemia and newonset congestive heart failure in the general Medicare population. J Card Fail 2005; 11(2): 99-105.
49. Brucks S, Little WC, Chao T, et al. Relation of anemia to diastolic heart failure and the effect on outcome. Am J Cardiol 2004; 93(8): 1055-7.
50. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35(2): 250-6.
51. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003; 18(1): 141-6.
52. Desai A, Lewis E, Solomon S, et al. Impact of erythropoiesisstimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. Eur J Heart Fail 2010; 12(9): 936-42.
53. McMurray JJ, Anand IS, Diaz R, et al. Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). Eur J Heart Fail 2013; 15(3): 334-41.
54. Simonds SE, Cowley MA. Hypertension in obesity: is leptin the culprit? Trends Neurosci 2013; 36(2): 121-32.
55. Masuo K, Rakugi H, Ogihara T, et al. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. Curr Diabetes Rev 2010; 6(2): 58-67.
56. Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care 2010; 33(2): 434-41.
57. Petersson M, Friberg P, Eisenhofer G, et al. Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J 2005; 26(9): 906-13.
58. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105(11): 1354-9.
59. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 2012; 33(9): 1058-66.
60. Volders PG. Novel insights into the role of the sympathetic nervous system in cardiac arrhythmogenesis. Heart Rhythm 2010; 7(12): 1900-6.
61. Zoccali C, Mallamaci F, Tripepi G, et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40(1): 41-6.
62. Nitenberg A, Ledoux S, Valensi P, et al. Impairment of coronary microvascular dilation in response to cold pressor--induced sympathetic stimulation in type 2 diabetic patients with abnormal stress thallium imaging. Diabetes 2001; 50(5): 1180-5.
63. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensinconverting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41(9): 1529-38.
64. Bell DS, Lukas MA, Holdbrook FK, et al. The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Curr Med Res Opin 2006; 22(2): 287-96.
65. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292(18): 2227-36.
66. Pollare T, Lithell H, Selinus I, et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298(6681): 1152-7.
67. Sica DA, Black HR. Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy. Curr Hypertens Rep 2008; 10(4): 330-5.
68. Lip GY, Shantsila E. Anticoagulation versus placebo for heart failure in sinus rhythm. Cochrane Database Syst Rev 2014; 3: CD003336.
69. McMurray JJ, Gerstein HC, Holman RR, et al. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014; 2(10): 843-51.